Actively Recruiting
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
Led by University of Utah · Updated on 2025-04-16
200
Participants Needed
1
Research Sites
264 weeks
Total Duration
On this page
Sponsors
U
University of Utah
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigue and improving physical function, independence, and quality of life. Participants will be asked to participate in a 52-week exercise intervention consisting of a twice weekly telehealth resistance training program.
CONDITIONS
Official Title
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Metastatic castration-sensitive prostate cancer patients without disease progression on current systemic therapy
- Currently treated with surgical or medical castration and/or androgen receptor pathway inhibitor started at least 12 weeks before enrollment
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- Not currently doing structured resistance training two or more days per week
- Regular access to an electronic device with internet and video call ability
- Access to or willingness to create an active MyChart account for the trial
- Willing to participate in home-based resistance exercise twice weekly
- Willing to take creatine monohydrate or placebo supplementation for 52 weeks and avoid other creatine or nutritional supplements during the study
- Willing to complete and submit weekly supplementation logs throughout the 52 weeks
- Willing to attend three in-person assessments at baseline, 24 weeks, and 52 weeks
- Able to provide informed consent and willing to sign the approved consent form
You will not qualify if you...
- Received cytotoxic chemotherapy within 12 weeks before enrollment
- Estimated Glomerular Filtration Rate (eGFR) below 30 ml/min/1.73m2
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 3 or higher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Actively Recruiting
Research Team
S
Susan Sharry
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here